Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Next generation cell therapies for solid tumours
Company stage: Clinical
Diseases: Multiple solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Private
Location: New York, USA
Intima Bioscience is a clinical-stage gene and cell therapy company focused on developing cures for solid cancers. The company develops tumour-infiltrating lymphocytes (TILs) in which the novel cytokine checkpoint CISH is disrupted using CRISPR. The company is currently testing its lead programme in multiple solid tumours in a Phase 1/2 clinical trial.